These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34561814)

  • 1. Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune® and Neoral® Lipid-Based Formulations.
    Warren DB; Haque S; McInerney MP; Corbett KM; Kastrati E; Ford L; Williams HD; Jannin V; Benameur H; Porter CJH; Chalmers DK; Pouton CW
    Pharm Res; 2021 Sep; 38(9):1531-1547. PubMed ID: 34561814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
    Williams HD; Anby MU; Sassene P; Kleberg K; Bakala-N'Goma JC; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Carrière F; Müllertz A; Pouton CW; Porter CJ
    Mol Pharm; 2012 Nov; 9(11):3286-300. PubMed ID: 23030411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
    Devraj R; Williams HD; Warren DB; Mohsin K; Porter CJ; Pouton CW
    Eur J Pharm Sci; 2013 Jul; 49(4):748-60. PubMed ID: 23684915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion.
    Birru WA; Warren DB; Han S; Benameur H; Porter CJ; Pouton CW; Chalmers DK
    Mol Pharm; 2017 Mar; 14(3):580-592. PubMed ID: 27936778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability.
    Tanaka Y; Nguyen TH; Suys EJA; Porter CJH
    Mol Pharm; 2021 Apr; 18(4):1768-1778. PubMed ID: 33729806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational and Experimental Models of Type III Lipid-Based Formulations of Loratadine Containing Complex Nonionic Surfactants.
    Guruge AG; Warren DB; Benameur H; Ford L; Williams HD; Jannin V; Pouton CW; Chalmers DK
    Mol Pharm; 2021 Dec; 18(12):4354-4370. PubMed ID: 34807627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
    Williams HD; Sassene P; Kleberg K; Calderone M; Igonin A; Jule E; Vertommen J; Blundell R; Benameur H; Müllertz A; Porter CJ; Pouton CW;
    J Pharm Sci; 2014 Aug; 103(8):2441-55. PubMed ID: 24985238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Structuring and Phase Transition of Lipid-Based Formulations upon Water Dispersion: A Coarse-Grained Molecular Dynamics Simulation Approach.
    Larsson P; Alskär LC; Bergström CAS
    Mol Pharm; 2017 Dec; 14(12):4145-4153. PubMed ID: 28799773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH
    Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?
    Alskär LC; Parrow A; Keemink J; Johansson P; Abrahamsson B; Bergström CAS
    J Control Release; 2019 Jun; 304():90-100. PubMed ID: 31047962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.
    Tanaka Y; Doi H; Katano T; Kasaoka S
    Eur J Pharm Sci; 2021 Feb; 157():105604. PubMed ID: 33098990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Dynamics Simulation Studies of Bile, Bile Salts, Lipid-Based Drug Formulations, and mRNA-Lipid Nanoparticles: A Review.
    Guruge AG; Warren DB; Pouton CW; Chalmers DK
    Mol Pharm; 2023 Jun; 20(6):2781-2800. PubMed ID: 37194978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA; Chalmers DK; Pouton CW; Porter CJH
    Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid determination of drug solubilization versus supersaturation in natural and digested lipids.
    Gautschi N; Bergström CA; Kuentz M
    Int J Pharm; 2016 Nov; 513(1-2):164-174. PubMed ID: 27609663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solubilisation behaviour of poorly water-soluble drugs during digestion of solid SMEDDS.
    Vithani K; Hawley A; Jannin V; Pouton C; Boyd BJ
    Eur J Pharm Biopharm; 2018 Sep; 130():236-246. PubMed ID: 29981444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption of cinnarizine from type II lipid-based formulations: Impact of lipid chain length, supersaturation, digestion, and precipitation inhibition.
    Paulus F; Holm R; Stappaerts J; Bauer-Brandl A
    Eur J Pharm Sci; 2024 Jun; 197():106765. PubMed ID: 38608735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro.
    Keemink J; Mårtensson E; Bergström CAS
    Mol Pharm; 2019 Mar; 16(3):921-930. PubMed ID: 30628771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictions of biorelevant solubility change during dispersion and digestion of lipid-based formulations.
    Ejskjær L; Holm R; Kuentz M; Box KJ; Griffin BT; O'Dwyer PJ
    Eur J Pharm Sci; 2024 Sep; 200():106833. PubMed ID: 38878908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glyceride lipid formulations: molecular dynamics modeling of phase behavior during dispersion and molecular interactions between drugs and excipients.
    Warren DB; King D; Benameur H; Pouton CW; Chalmers DK
    Pharm Res; 2013 Dec; 30(12):3238-53. PubMed ID: 24092054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.